The present study aimed to assess the B rapidly accelerated fibrosarcoma (BRAF<sup>V600E</sup>) status in plasma from Chinese patients with melanoma, and evaluated its prognostic value following treatment with BRAF inhibitors.
G-F is a potent and selective B-Raf (rapidly accelerated fibrosarcoma) inhibitor with poor water solubility and moderate permeability, which resulted in an absorption-limited exposure in preclinical safety studies.